

COVID 19 Pseudoviral Particles, Indian B.1.617 Coronavirus Pseudovirus | COVID-19 pseudovirus

SARS-CoV-2 Pseudoviral Particles, Indian B.1.617 Variant

CATALOG #

AAA62231


PRODUCT SYNONYMS

COVID 19 Pseudoviral Particles; Indian B.1.617 Coronavirus; SARS-CoV-2 Pseudoviral Particles; Indian B.1.617 Variant; 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Pseudoviral Particles; COVID-19 pseudovirus

PRODUCT SPECIFICATIONS


Form/Format	10 ml (2 tubes, 5 mL/tube), for 2 multi-well plates
Features	Robust: Excellent signal to noise (basal) ratio Easy to use: Amenable to HTS format (96-well, 384-well and 1536-well format)
Dry Ice Note	The product may be shipped with dry ice, and an additional fee may be added to your shipping cost.
Preparation and Storage	Ships on dry ice. Store at -70°C. Dry Ice Shipment: Extra charge fee may add to your shipping cost as dry ice is required to ship this product. Shipping Note: Product is available for shipment in the United States, Canada and European countries. Please inquire for shipment to other countries.

IMAGES




Application Data

Figure 4. Antibody (Ab) Neutralization Assays with SARS-CoV-2-614G-PP




Application Data

Figure 3. SARS-CoV-2 Viral Infection Inhibiting Test by Neutralization Antibodies. HEK293-ACE2 cells incubated with SARS-CoV-2 India Variant Pseudoviral Particles (AAA62231) under various amount of neutralizing antibody. Legend: SARS-CoV2-India-PP, SARS-CoV-2 India variant Pseudoviral Particles "Control", neutralizing antibody used in this viral infection inhibition assay.



Application Data

Figure 2. Pseudoviral Particle (PP) Infection Assays SARS-CoV-2-IN variant pseudoviral particles on HEK293-ACE2 cells in 384-well format. Legends: SARS-CoV-2-India-PP: SARS-CoV-2 Indian B.1.617 variant MLV Pseudovirus Particles (AAA62231)(-): MLV control (w/o envelope spike protein)



Application Data

Figure 1. Illustration of the replication-deficient MLV particle pseudotyped with SARS-CoV-2 Spike protein

ADDITIONAL INFORMATION

Related Product Information for COVID-19 pseudovirus	SARS-CoV-2 Pseudoviral Particles, replication-deficient MLV pseudotyped with the SARS-CoV-2 spike protein (the Indian B.1.617 variant). The SARS-CoV-2 Pseudoviral Particles are replication-deficient Maloney murine leukemia virus (MLV) pseudotyped with the SARS-CoV-2 spike protein of the Indian B.1.617 variant (GISAID sequence accession number EPI_ISL_1547802). It has been known that SARS coronavirus 2 (SARS-CoV-2) uses human ACE2 as entry receptor and human proteases as entry activators. The virus surface spike protein (S) mediates SARS-CoV-2 entry into cells. To fulfill its function, SARS-CoV-2 spike binds to its human ACE2 (hACE2) receptor through its receptor-binding domain (RBD) and is proteolytically activated by human proteases. Our SARS-CoV-2-IN Pseudoviral Particles are replication-deficient MLV pseudotyped with the SARS-CoV-2 spike protein of the Indian variant B.1.617, also known as G/452R.V3, (GISAID sequence accession number EPI_ISL_1547802). They also contain the ORF for firefly luciferase as a reporter. They establish a pseudovirus entry assay for SARS-CoV-2 as the spike protein mediated cell entry can be conveniently measured via luciferase reporter activity. This pseudovirus assay isolates the SARS-CoV-2 viral entry from other steps of the viral infection cycle.
--	---

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/covid-19-pseudovirus/covid-19-pseudoviral-particles-indian-b-1-617-coronavirus/62231>